Status Migrainosus Management

Diagnostic Considerations

The American Academy of Neurology suggests that a 7-month progressive worsening pattern is atypical for primary migraine, which typically has a more stable course over time 2
The American College of Emergency Physicians notes that a normal head CT does not exclude all secondary causes, such as venous sinus thrombosis, intracranial hypotension, or early mass lesions 2
Given a normal CT and labs, and assuming no other red flags, the American Academy of Family Physicians recommends proceeding with status migrainosus treatment 3, 2

The American Headache Society recommends IV dihydroergotamine (DHE) as the gold standard for status migrainosus in the inpatient setting, with well-established efficacy for breaking prolonged migraine cycles 1
The American College of Physicians suggests administering DHE 0.5-1 mg IV every 8 hours for 2-3 days, with pre-treatment with metoclopramide 10 mg IV or prochlorperazine 10 mg IV 30 minutes before each DHE dose 1
The American Academy of Neurology notes that DHE has 47-70% efficacy for acute migraine relief within 4 hours, with sustained benefit over 24 hours 1

The American College of Rheumatology recommends adding IV methylprednisolone 80-125 mg daily or dexamethasone 10-20 mg IV for 2-3 days to break the status migrainosus cycle 1
The American Academy of Family Physicians suggests that corticosteroids are specifically indicated for status migrainosus, not routine acute migraine, to reduce inflammation and prevent recurrence 1

The American Headache Society defines medication-overuse headache (MOH) as occurring when acute medications are used >2 days per week (>10 days/month for triptans, >15 days/month for NSAIDs) 1
The American Academy of Neurology notes that the progressive worsening pattern and minimal response to treatment are classic for MOH 3, 1

The American Academy of Neurology recommends initiating or optimizing preventive therapy for patients with >2 attacks per month producing disability for >3 days 3
The American Headache Society suggests first-line preventive options, including propranolol 80-240 mg/day, topiramate 50-200 mg/day, or amitriptyline 30-150 mg/day 1
The American College of Physicians notes that CGRP monoclonal antibodies should be considered if oral preventives fail, with efficacy assessed after 3-6 months 1

The American Academy of Family Physicians recommends providing rescue medication, such as subcutaneous sumatriptan 6 mg or nasal DHE, for breakthrough attacks 3, 1
The American Headache Society suggests strict education on medication frequency limits, with no more than 2 days per week for any acute medication 3, 1